| Theme | Glucocorticoid-induced osteoporosis and bone metabolism | |
|---|---|---|
| Title | Guidelines for prevention and treatment of glucocorticoid-induced osteoporosis | |
| Publish Date | 2006/04 | |
| Author | Satoshi Soen | Department of Orthopaedic Surgery and Rheumatology, Nara Hospital, Kinki University School of Medicine |
| [ Summary ] | Osteoporosis is the most frequent adverse effect of glucocorticoid administration. Management guidelines for glucocorticoid-induced osteoporosis have been established in the United States, the United Kingdom, and many other countries. The 2004 edition of the guidelines for the management and treatment of glucocorticoid-induced osteoporosis have been proposed by The Japanese Society for Bone and Mineral Research. The subjects were patients using or planning to use oral glucocorticoids for 3 months or longer. The criteria for starting treatment were patients with prior fragility fractures, those with new fractures during treatment, patients with BMD lower than % YAM 80, and patients with receiving dosages of 5 mg / day or higher (mean daily dose) as prednisolone replacements. Bisphosphonates have been recommended as first line drugs and active vitamin D3 and vitamin K2 hsve been recommended as second line drugs. | |